alnylam pharmaceuticals inc
John K. Clarke
Founder, Chairman, Chairman of Nominating & Corporate Governance Committee and Member of Audit Committee, Alnylam Pharmaceuticals, Inc.
|Age||Total Calculated Compensation||This person is connected to 89 board members in 4 different organizations across 7 different industries.|
See Board Relationships
Mr. John K. Clarke co-founded Cardinal Partners in 1997 and has been its Managing General Partner since October 1997. Mr. Clarke spent two decades in venture capital industry, which he entered in 1982. Mr. Clarke served as General Partner at DSV. During his tenure there, he led its health care and life sciences efforts and co-founded and served as an Interim Chief Executive Officer of a number of companies including Alkermes, Arris Pharmaceuticals, the DNX Corporation, ...
300 Third StreetPhone: 617-551-8200
Cambridge, Massachusetts 02142
Board Members Memberships*
Former Director, Member of Audit Committee and Member of Compensation Committee
Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
Founder, Chairman, Chairman of Nominating & Corporate Governance Committee and Member of Audit Committee
Independent Director, Chairman of Compensation Committee and Member of Audit Committee
Director and Member of Audit Committee
Former Director and Member of Audit Committee
University of Pennsylvania - The Wharton School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|Ali Mortazavi||Chief Executive and Director|
Silence Therapeutics plc
|George W. Hebard III, M.B.A||Interim Principal Executive Officer, Interim Chief Operating Officer and Secretary|
Enzon Pharmaceuticals Inc.
|Peter French B.Sc, M.Sc, Ph.D., MBA||Chief Executive Officer, Managing Director and Director|
Benitec Biopharma Limited
|Mark W. Schwartz Ph.D.||Chief Executive Officer, President and Director|
Galena Biopharma, Inc.
|Mark J. Murray Ph.D.||Chief Executive Officer, President and Director|
Tekmira Pharmaceuticals Corporation
|$377.5K||Compensation as of Fiscal Year 2013.|